NCT01698554

Bimatoprost in the Treatment of Eyelash Hypotrichosis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 464 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety and efficacy of bimatoprost solution formulation A compared with bimatoprost solution 0.03% (LATISSE®) and vehicle in the treatment of eyelash hypotrichosis (inadequate eyelashes).

Conditions

• Idiopathic Eyelash Hypotrichosis

Interventions

Type	Name	Description
DRUG	bimatoprost formulation A solution	Bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
DRUG	bimatoprost solution 0.03 %	Bimatoprost solution 0.03 % (LATISSE®) applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
DRUG	vehicle of bimatoprost formulation A solution	Vehicle of bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
DRUG	vehicle of bimatoprost solution 0.03 %	Vehicle of bimatoprost solution 0.03 % applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.

Timeline

• Start date: 2012-11-01
• Primary completion: 2014-02-01
• Completion: 2014-03-01
• First posted: 2012-10-03
• Last updated: 2015-02-10
• Results posted: 2015-02-10

Locations

4 sites across 4 countries: United States, Russia, Sweden, United Kingdom